Dichloroacetate (DCA) can enhance metformin-induced oxidative damage with simultaneous reduce of metformin promoted lactate production through PDK1 inhibition, suggesting the innovative combinations, such as metformin and DCA, will be promising in expanding breast cancer therapies (302). The gene discussed is PDK1; the disease is breast carcinoma.